Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Jun;26(6):451-8.
doi: 10.1007/BF02536072.

Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol-fed rats

C Guettet  1 , N Rostaqui, D Mathé, B Lecuyer, N Navarro, B Jacotot
Affiliations

Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol-fed rats

C Guettet et al. Lipids. 1991 Jun.

Abstract

Male adult Wistar rats received daily (at 9 a.m. and 5 p.m.) 10 micrograms of zinc-protamine glucagon by subcutaneous injection for 8 days. Plasma cholesterol levels were decreased by 36% in fed rats, 33% in cholesterol-fed rats and by 55% in fasted rats. Lipoproteins were separated into 22 fractions by ultracentrifugation using a density gradient. Glucagon administration decreased the cholesterol content in all lipoproteins except low density lipoprotein (LDL1) (1.006-1.040) and very low density lipoprotein (VLDL) from cholesterol-fed rats. The main decrease (-57 to -81%) was observed in 1.050-1.100 g/mL lipoproteins (LDL2 and HDL2), which contained a large amount of apo E, while HDL3 cholesterol was not affected. Triacylglycerol levels were decreased only in chylomicrons and VLDL (-70%) of fed and cholesterol-fed rats, while plasma and lipoprotein triacylglycerol levels were not changed in fasted rats treated with glucagon. In normally fed rats glucagon administration increased by 42% the fractional catabolic rate of [125I]HDL2 while the absolute catabolic rate appeared to be unchanged. Glucagon seems to be a potent hypolipidemic agent affecting mainly the apo E-rich lipoproteins. Its chronic administration limits lipoprotein accumulation which occurs upon cholesterol feeding.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Lipid Res. 1981 Aug;22(6):971-89 - PubMed
    1. J Biol Chem. 1961 Apr;236:1006-12 - PubMed
    1. Anal Biochem. 1975 May 12;65(1-2):42-9 - PubMed
    1. Biochim Biophys Acta. 1984 May 11;793(3):435-40 - PubMed
    1. J Lipid Res. 1987 Jul;28(7):847-55 - PubMed

MeSH terms

LinkOut - more resources

-